Business
Medicenna Presents Promising Clinical Data from Phase 2b Recurrent Glioblastoma Trial of MDNA55
Medicenna Presents Promising Clinical Data from Phase 2b Recurrent Glioblastoma Trial of M...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Presents Promising Clinical Data from Phase 2b Recurrent Glioblastoma Trial of MDNA55\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prngen3{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, TX, Feb. 7, 2019\n\n\n\nStrong interim survival trend (15.2 vs 8.5 months) emerging in IL4R positive patients \n TORONTO and HOUSTON, TX, Feb. 7, 2019 /CNW/ - Medicenna Therapeutics Corp.  (\"Medicenna\" or \"the Company\") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunotherapy company developing first-in-class Superkines and Empowered Cytokines, reported interim data from its on-going Phase 2b trial of MDNA55 for the treatment of recurrent glioblastoma (\"rGBM\"). MDNA55 is a fusion protein designed to target the Type II interleukin-4 receptor (consisting of the IL4Rα  and IL13Rα 1), a biomarker that is over-expressed in a majority of GBM patients but not in healthy brain. GBM patients with a positive Type 2 IL4R profile typically have a worse prognosis than the overall glioblastoma population, including poor long term survival. Results being presented today demonstrate promising signs of clinical benefit, particularly in recurrent patients with an aggressive form of GBM. \n\nNew clinical study results will be delivered today in a podium presentation titled, \"The IL4 Receptor as a Biomarker and Immunotherapeutic Target for Glioblastoma: Preliminary Evidence with MDNA55, a Locally Administered IL-4 Guided Toxin\" by John H. Sampson, MD, PhD, Robert H. and Gloria Wilkins Distingui...